证券代码：603233 证券简称：大参林 公告编号：2024-110 大参林医药集团股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 11 月 18 日(星期一)至 11 月 22 日(星期五)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 DSL1999@dslyy.com 行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 大参林医药集团股份有限公司（以下简称"公司"）已于 2024 年 10 月 31 日发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 年前三季度经营情况及财务状况，公司计划于 2024 年 11 月 25 日下午 14:00-15:00 举行 2024 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以 ...

证券代码：603233 证券简称：大参林 公告编号：2024-109 二、控股股东的质押情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次股份解除质押的具体情况 2024 年 11 月 8 日，公司收到相关通知，柯金龙将其质押的部分股份 14,562,144 股解除质押，并已完成解除质押登记手续。具体情况如下: | 股东名称 | 柯金龙 | | --- | --- | | 本次解除质押股份数量（股） | 14,562,144 | | 占其所持有股份比例（%） | 6.34 | | 占公司总股本比例（%） | 1.28 | | 解质时间 | 2024年11月7日 | | 持股数量（股） | 229,631,849 | | 持股比例（%） | 20.16 | | 剩余被质押股份数量（股） | 61,280,000 | | 剩余被质押股份数量占其所持有股份比例（%） | 26.69 | | 剩余被质押股份数量占公司总股本比例（%） | 5.38 | 大参林医药集团股份有限公司 关于控股股东部分股份解除质 ...

2024 年第五次临时股东大会会议材料 大参林医药集团股份有限公司 2024 年第五次临时股东大会 会议材料 二○二四年十一月 2024 年第五次临时股东大会会议材料 目 录 | 2024 | 年第五次临时股东大会会议议程 | 1 | | --- | --- | --- | | 2024 | 年第五次临时股东大会会议须知 | 3 | | 2024 | 年第五次临时股东大会会议议案 | 4 | | | 议案一：关于向下修正"大参转债"转股价格的议案 | 4 | 2024 年第五次临时股东大会会议材料 大参林医药集团股份有限公司 2024 年第五次临时股东大会会议议程 会议表决方式：现场投票与网络投票相结合的方式 会议时间：2024 年 11 月 18 日上午 10 点 30 分 网络投票：2024 年 11 月 18 日 网络投票起止时间：采用上海证券交易所网络投票系统，通过交易系统投票 平台的投票时间为股东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30， 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 会议地点：广东省广州市荔湾区龙溪大 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 19.731 billion yuan for the first three quarters of 2024, representing an increase of 11.33% year-on-year, while the net profit attributable to shareholders was 858 million yuan, a decrease of 26.93% [2] - The wholesale business is experiencing rapid growth, with a significant increase in demand for traditional Chinese and Western medicine, while the number of stores continues to rise [3] - The company aims to enhance its market share in newly entered provinces through a combination of direct management and franchise models [3] - Adjustments have been made to the profit forecasts for 2024-2026 due to the challenging consumption environment in the Guangdong region and the impact of new store openings [4] Financial Performance - Total revenue for 2022 was 21.248 billion yuan, with a projected increase to 26.728 billion yuan in 2024, reflecting a growth rate of 8.96% [1] - The net profit attributable to shareholders for 2022 was 1.036 billion yuan, with a forecasted decline to 1.026 billion yuan in 2024, indicating a decrease of 12.02% [1] - The company has seen a steady increase in store numbers, reaching 16,453 stores by the end of Q3 2024, with a net increase of 2,379 stores in the first three quarters [3] - The gross margin for retail revenue was 37.26%, while the wholesale gross margin was 10.94% [3] Store Expansion and Market Strategy - The company has been actively expanding its store network, with a focus on direct management in key provinces and increasing franchise operations in new regions [3] - The company plans to continue its strategy of enhancing market share through both self-built and acquired stores, as well as franchise partnerships [3]

Investment Rating - The report does not specify a clear investment rating for the company [1]. Core Insights - The company reported a revenue of 19.73 billion yuan for the first three quarters of 2024, representing an increase of 11.3% year-on-year, while the net profit attributable to shareholders decreased by 26.3% to 860 million yuan [1][2]. - The company continues to expand its franchise stores rapidly, with a total of 16,453 chain stores nationwide, including 5,735 franchise stores, maintaining the leading position in the pharmaceutical retail industry [2][3]. - The company’s gross profit margin for Q1-Q3 2024 was 34.7%, a decrease of 2.4 percentage points compared to the previous year [2]. Financial Performance Summary - For Q3 2024, the company achieved a revenue of 6.39 billion yuan, up 11.4% year-on-year, and a net profit of 200 million yuan, down 22.0% year-on-year [1][2]. - The company’s revenue for Q1-Q3 2024 was 6.75 billion yuan, 6.59 billion yuan, and 6.39 billion yuan respectively, with year-on-year growth rates of 13.5%, 9.1%, and 11.4% [2]. - The company’s net profit for Q1-Q3 2024 was 400 million yuan, 260 million yuan, and 200 million yuan respectively, with year-on-year declines of 19.8%, 38.4%, and 22% [2]. Profit Forecast - The forecast for net profit attributable to shareholders is 1.1 billion yuan in 2024, 1.05 billion yuan in 2025, and 1.23 billion yuan in 2026, with growth rates of -9.75%, 16.94%, and 20.33% respectively [3][4]. - The company expects revenue growth rates of 9.31% in 2024, 18.41% in 2025, and 18.54% in 2026 [4][7]. Business Expansion Strategy - The company is focused on deepening its presence in South China while expanding nationwide through self-built, acquired, and direct franchise models [2][3]. - The company added 2,379 new stores in Q1-Q3 2024, with 1,570 of these being franchise stores, indicating a mature development of its direct franchise business [2].

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 18.7 yuan [1]. Core Views - The company's performance in the first three quarters of 2024 met expectations, with revenue of 19.73 billion yuan, a year-on-year increase of 11.3%, while net profit attributable to shareholders decreased by 26.9% to 860 million yuan [1]. - The retail segment showed steady growth, with revenue of 16.35 billion yuan, up 9.7% year-on-year, and a gross margin of 37.3% [1]. - The company is dynamically adjusting its store expansion pace, focusing on quality development, with a total of 16,453 stores as of Q3 2024, a year-on-year increase of 26.6% [1]. - Short-term gross margins are under pressure, with a gross margin of 34.2% in Q3 2024, down 2.0 percentage points year-on-year [1]. Financial Summary - For 2024, the company expects net profit attributable to shareholders to be 1.03 billion yuan, a decrease of 12% year-on-year, followed by a recovery with growth rates of 15% in 2025 and 2026 [1][5]. - The total revenue forecast for 2024 is 27.6 billion yuan, with a year-on-year growth rate of 12.5% [2]. - The company’s total assets are projected to reach 26.7 billion yuan in 2024, with a debt-to-asset ratio of 36.07% [3][5].

| 证券代码：603233 | 证券简称：大参林 | 公告编号：2024-107 | | --- | --- | --- | | 转债代码：113605 | 转债简称：大参转债 | | 大参林医药集团股份有限公司关于 董事会提议向下修正"大参转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1、2020年12月23日，公司完成了2020年度限制性股票激励计划首次授予的 登记工作，公司总股本由656,340,654股变更为658,621,154股。由于公司股本发生 自2024年10月14日至2024年11月1日期间，大参林医药集团股份有限公司（以 下简称"公司"）股票已满足在任意连续三十个交易日中至少有十五个交易 日的收盘价低于当期转股价格即46.49元/股的85%（即39.51元/股），已触发 "大参转债"转股价格的向下修正条款。 经公司第四届董事会第二十一次会议审议，董事会提议向下修正"大参转债" 的转股价格。 本次向下修正"大参转债"转股价格尚需提交至股东大会审议。 变化，需对"大参转债"的转股价格作出 ...

证券代码：603233 证券简称：大参林 公告编号：2024-108 大参林医药集团股份有限公司 关于召开 2024 年第五次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 网络投票系统：上海证券交易所股东大会网络投票系统 股东大会召开日期：2024年11月18日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 网络投票起止时间：自 2024 年 11 月 18 日 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024 年第五次临时股东大会 召开的日期时间：2024 年 11 月 18 日 10 点 30 分 召开地点：广州市荔湾区龙溪大道 410 号大参林集团综合楼 4 楼会议室 (五) 网络投票的系统、起止日期和投票时间。 至 2024 年 11 月 18 日 采用上海证券交易所网络投票系统，通过交易系统 ...

大参林医药集团股份有限公司 第四届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603233 证券简称：大参林 公告编号：2024-106 一、董事会会议召开情况 大参林医药集团股份有限公司（以下简称"公司"）第四届董事会第二十一 次会议于 2024 年 11 月 1 日以通讯方式召开，本次会议应到董事 7 人，实到董事 7 人。本次会议由董事长柯云峰先生召集并主持，公司部分高级管理人员列席了 会议。本次会议的出席人数、召集、召开及表决程序均符合《中华人民共和国公 司法》等法律法规、行政部门规章、规范性文件和《大参林医药集团股份有限公 司章程》的规定，会议决议合法有效。 二、董事会会议审议情况 1、审议通过《关于向下修正"大参转债"转股价格的议案》 截止2024年11月1日，公司股价出现连续三十个交易日中已有十五个交易日 的收盘价低于当期转股价格的85%的情形，已触发"大参转债"的向下修正条款。 为支持公司长期稳健发展，维护投资者权益，公司董事会提议向下修正"大 参转债 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][6]. Core Views - The company has achieved rapid revenue growth due to its expansion outside the province, although profitability is under pressure. Efforts to optimize gross margin and cost structure are showing initial results [2][4]. - For Q3 2024, the company reported revenue of 6.386 billion yuan (+11.4%) and a net profit attributable to shareholders of 201 million yuan (-22%). The performance is generally in line with expectations [4]. - The EPS forecast for 2024-2026 has been revised down to 0.90/1.06/1.23 yuan from the previous 1.07/1.24/1.43 yuan, reflecting the impact of rapid expansion on profitability [4]. Revenue and Profitability - The company’s revenue for Q3 2024 was 6.386 billion yuan, with retail and wholesale segments achieving revenues of 5.287 billion yuan (+13.0%) and 978 million yuan (+12.5%) respectively [4]. - The gross margin for Q3 2024 was 34.2%, down 2.0 percentage points, but the decline has narrowed. The pressure on gross margin is primarily due to the lower margin from the increased share of out-of-province sales [4]. - The company is actively implementing cost control measures, with management expenses showing a decreasing trend [4]. Business Expansion - As of Q3 2024, the total number of stores reached 16,453, with a year-on-year growth of 27% for total stores and 15% for direct stores. However, the pace of new store openings has slightly slowed, and 452 stores were closed in the first three quarters of 2024 [4][6]. - The company is focusing on optimizing operational quality through the closure of underperforming stores [4]. Financial Summary - The company’s total revenue is projected to grow from 24.531 billion yuan in 2023 to 36.235 billion yuan in 2026, reflecting a compound annual growth rate of approximately 14% [5][10]. - The net profit attributable to shareholders is expected to decline in 2024 to 1.022 billion yuan, before recovering to 1.406 billion yuan by 2026 [5][10]. - The company’s price-to-earnings ratio is projected to be 16.15 in 2024, decreasing to 11.73 by 2026 [5][10].